Testing is the New Normal: Protecting Our Communities, Workplaces and Schools

2021 marked an impressive pipeline of innovative diagnostics, vaccines, next generation medicines and public health interventions as the world came together in the fight against COVID-19.  With breakthrough variants like Delta and Omicron, it became clear that no one solution would be enough to end the pandemic; it must be vaccines in partnership with testing.

Since the start of the pandemic, Abbott, a global leader in healthcare, has been all in. We developed 12 tests in 12 months – from rapid antigen and molecular tests to PCR and antibody tests done in the lab and shipped more than 1 billion COVID-19 tests around the world to help slow the spread of infection.

To get tests where they were needed most, we introduced testing in new decentralised channels, from clinics and pharmacies to high traffic areas, as well as return to normality screening programs (in partnership with governments and the private sector), and at-home and OTC testing.

With the advent of the new year and more transmissible variants causing spikes in cases, it’s more critical than ever to maintain open economies and ensure freedom and peace of mind for companies and individuals through reliable, affordable and accessible COVID-19 testing.   As of 5 January, new daily cases in Romania have risen +197% vs previous week.  This is compounded by a rise of Omicron cases, and likelihood of newly emergent SARS-CoV-2 variants.

To help ensure business continuity and safety, many governments and employers are using the Panbio™ COVID-19 Antigen Rapid Test Device, for professional use, to facilitate frequent, mass screenings in airports, “back to work” testing, mass gathering events and other activities in order to reopen and sustain business operations. 

• Panbio COVID-19 Ag Rapid Test Device is a CE marked, easy-to-use, lateral flow assay for rapid, qualitative detection of SARS-CoV-2–it delivers results in 15 minutes with no instrumentation. It has WHO Emergency Use Listing for nasopharygeal and nasal sample collection on asymptomatic and symptomatic people.   
• Panbio is one of the mostly widely studied rapid antigen tests in the world. In clinical evaluations of Panbio Covid-19 Antigen Rapid Test Device, performed by healthcare professionals, the test correctly identified 98.1% of positive specimens and 99.8% of negative specimens.

Designed to be fast, reliable and easy-to-use, Abbott’s COVID-19 tests are available in point of care settings to be closer to the people who need them. Available in packages to support a variety of testing needs, the Panbio COVID-19 Antigen Self-Test comes in one, four, and 10 count test kits for individual testing; it also comes in 20 test kits to meet workplace screening needs.

Backed by more than 130 years in healthcare innovation, Abbott will continue to advance COVID-19 and infectious disease diagnostics, and enable better preparedness for future pandemics and viral threats. 

FOR MORE INFORMATION, CONTACT (Romania): diana.frunza@abbott.com and tudor.voina@mediclim.ro

VISIT GPOC.ABBOTT and SELFTEST.ABBOTT

Product not available in all countries. Not approved for sale in the USA.

© 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.